Small-molecule senoblockers targeting senescent cells—cells that stop dividing and accumulate with age. Modulates chromatin to eliminate senescent cells or restore their function.
Preclinical; acquired from Dorian in May 2025. Lead candidates in lung fibrosis and osteoarthritis models.
Checked 10 Oct0 updates this week
Senescent cells stop dividing but persist in tissues, secreting inflammatory factors and contributing to fibrosis and joint degeneration.
Small molecules modulate chromatin accessibility and epigenetic regulators, enabling removal of senescent cells or restoration of repair functions.
Reducing senescent cell burden or reactivating their beneficial functions aims to halt fibrosis and restore joint function.
| Spec | Senoblockers |
|---|---|
| Mechanism | Epigenetic modulators targeting senescent cellsR (reported) |
| Lead indications | Lung fibrosis, osteoarthritisR (reported) |
R reported by the company
Altos Labs
Making old cells young again
Launched in Jan 2022 with $3B, the biggest start ever for an aging company. Altos runs research labs in the Bay Area, San Diego and Cambridge, UK, where top reprogramming scientists study how to make cells young and healthy again to reverse disease.
